Dynamics of ischaemia-modified albumin in acute ischaemic stroke
Keywords:
Serum biomarkers, brain ischemia, ischaemiamodified albumin, strokeAbstract
A variety of biomarkers have been evaluated to aid the early diagnosis of brain ischemia, to distinguish from different stroke mimics, to stratificate patients for thrombolytic therapy and to predict stroke severity and outcome. Ischemia-modified albumin (IMA) is a relatively novel biomarker for rapid detection of brain ischaemia. The serum levels of IMA increase in the acute phase of ischemic stroke and gradually decline over time.
We analyzed data on 43 patients who presented with acute ischaemic stroke and studied the dynamics of IMA levels in the acute phase of brain ischaemia compared to 72 hours after the onset of neurological deficits.
References
Natsionalen konsensus za profilaktika, diagnoza i lechenie na mozŭchno-sŭdovite zabolyavaniya. Bŭlgarska nevrologiya, 19, 2018.
Abboud, H., Labreuche, J., Meseguer, E., Lavallee, P.C., Simon, O., Olivot, J.M., Mazighi, M., Dehoux, M., Benessiano, J., Steg, P.G., Amarenco, P. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis, 2007, 23, 2-3, 216-220.
Adams, H.P. Jr, Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L., Marsh, E.E. 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24, 1, 35–41.
Can, S., Akdur,O., Yildirim, A., Adam, G., Cakir, D., Karama,O., Myelin basic protein and ischemia modified albumin levels in acute ischemic stroke cases, Journal of Medical Science, 2015, 1110–1114.
Gad, S., Zakaria, H.,Elgayar, H., Evaluation of therole of ischemiamodifiedalbuminas a newbiochemicalmarker for differentiationbetweenischemic and hemorrhagicstroke. Alexandriajournal of medicine, 2015, 213–217.
Gunduz, A., Turedi, S., Mentese, A., Altunayoglu, V., Turan, I., Karahan, S.C., Topbas, M., Aydin, M., Eraydin, I., Akcan, B. Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med, 2008, 26, 8, 874-888.
Herisson, F., Delaroche, O., Auffray-Calvier, E., Duport, B.D., Guillon, B. Ischemia-modified Albumin and Heart Fatty Acid–binding Protein: Could Early Ischemic Cardiac Biomarkers Be Used in Acute Stroke Management? J Stroke Cerebrovasc Dis, 2010, 19, 4, 279-282.
Jena, I., Nayak, S., Behera, S., Singh, B., Ray, S., Jena, D., Singh, S., Sahoo, S.K. Evaluation of ischemia-modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients. J Nat Sc Bio lMed, 2017, 8, 110-113.
Liberman, A.L., Liotta, E.M., Caprio, F.Z., Ruff, I., Maas, M.B., Bernstein, R.A., Khare, R., Bergman, D., Prabhakaran, S. Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates? Neurol Clin Pract, 2015, 5, 3, 247-252.
Menon, B., Ramalingam, K., Krishna, V. Study of Ischemia Modified Albumin as a Biomarker in Acute Ischaemic Stroke. Ann Neurosci, 2018, 25, 4, 187–190.
Merino, J.G., Luby, M., Benson, R.T., Davis, L.A., Hsia, A.W., Latour, L.L., Lynch, J.K., Warach, S. Predictors of acutestrokemimics in 8,187 patients referred to a strokeservice. J Stroke Cerebrovasc Dis, 2013, 22, 8, 397-403.
Tobin, W.O., Hentz, J. G., Bobrow, B. J., Demaerschalk, B. M., Identification of strokemimics in the emergency department Setting. Journal of brain disease, 2009, 19–22.
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2019 Marina Krasteva, N. Muradian, E. Naseva, J. Hristova, P. Gecov, R. Kalpachki, E. Vassileva
This work is licensed under a Creative Commons Attribution 4.0 International License.
